Birdwatch Archive

Birdwatch Note

2024-11-04 18:09:56 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

動画は2つ違う全く違う安全性の検証を受けているものをほぼ同じ条件としており、誤解を招きます。 新型コロナワクチンは食品類と違い4万人の臨床試験を行い副反応の疑いのある重篤な有害事象見られず↓と確認された後、承認され https://www3.nhk.or.jp/news/html/20210212/k10012863501000.html また販売後も例えば腎疾患に関して4つの研究で百万~数百万の方のデータから接種直後や接種者に腎不全等の腎疾患の客観的な新規医療記録のリスク増加が検出できない事が報告され↓ https://www.nejm.org/doi/full/10.1056/nejmoa2110475 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004018 https://link.springer.com/article/10.1007/s40264-023-01332-1 https://www.sciencedirect.com/science/article/pii/S0085253822006974 こうした安全性有効性のデータ評価を元にWHOも米CDCも欧EMAもワクチンのリスクベネフィット比が良好とし特定対象に推奨中です。 https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/safety-covid-19-vaccines#:~:text=The%20safety%20profiles%20of%20the,few%20of%20these%20rare%20cases.

Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1853433182030541231

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1853499940758225067
  • noteId - 1853499940758225067
  • participantId -
  • noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
  • createdAtMillis - 1730743796897
  • tweetId - 1853433182030541231
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 1
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 0
  • misleadingSatire - 1
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • 動画は2つ違う全く違う安全性の検証を受けているものをほぼ同じ条件としており、誤解を招きます。 新型コロナワクチンは食品類と違い4万人の臨床試験を行い副反応の疑いのある重篤な有害事象見られず↓と確認された後、承認され https://www3.nhk.or.jp/news/html/20210212/k10012863501000.html また販売後も例えば腎疾患に関して4つの研究で百万~数百万の方のデータから接種直後や接種者に腎不全等の腎疾患の客観的な新規医療記録のリスク増加が検出できない事が報告され↓ https://www.nejm.org/doi/full/10.1056/nejmoa2110475 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004018 https://link.springer.com/article/10.1007/s40264-023-01332-1 https://www.sciencedirect.com/science/article/pii/S0085253822006974 こうした安全性有効性のデータ評価を元にWHOも米CDCも欧EMAもワクチンのリスクベネフィット比が良好とし特定対象に推奨中です。 https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/safety-covid-19-vaccines#:~:text=The%20safety%20profiles%20of%20the,few%20of%20these%20rare%20cases.

Note Ratings

rated at rated by
2024-11-04 18:21:56 -0600 Rating Details
2024-11-04 18:10:56 -0600 Rating Details
2024-11-04 14:41:06 -0600 Rating Details
2024-11-04 14:30:39 -0600 Rating Details
2024-11-04 14:17:54 -0600 Rating Details
2024-11-04 14:09:36 -0600 Rating Details
2024-11-04 13:54:35 -0600 Rating Details
2024-11-04 13:15:06 -0600 Rating Details
2024-11-04 12:26:56 -0600 Rating Details
2024-11-05 15:53:49 -0600 Rating Details
2024-11-05 09:22:12 -0600 Rating Details
2024-11-05 09:21:48 -0600 Rating Details
2024-11-05 09:16:17 -0600 Rating Details
2024-11-05 08:30:54 -0600 Rating Details
2024-11-05 07:12:36 -0600 Rating Details
2024-11-05 06:40:15 -0600 Rating Details
2024-11-05 06:19:27 -0600 Rating Details
2024-11-05 06:07:47 -0600 Rating Details
2024-11-05 03:36:13 -0600 Rating Details
2024-11-05 03:11:09 -0600 Rating Details
2024-11-05 02:59:55 -0600 Rating Details
2024-11-05 01:54:44 -0600 Rating Details
2024-11-05 01:43:48 -0600 Rating Details
2024-11-05 01:41:34 -0600 Rating Details
2024-11-05 01:02:46 -0600 Rating Details
2024-11-05 01:01:05 -0600 Rating Details
2024-11-05 00:42:34 -0600 Rating Details
2024-11-05 00:18:46 -0600 Rating Details
2024-11-04 23:57:59 -0600 Rating Details
2024-11-04 23:55:49 -0600 Rating Details
2024-11-04 22:20:53 -0600 Rating Details
2024-11-04 21:51:30 -0600 Rating Details
2024-11-04 21:34:27 -0600 Rating Details
2024-11-04 21:23:52 -0600 Rating Details
2024-11-04 21:19:56 -0600 Rating Details
2024-11-04 21:19:10 -0600 Rating Details
2024-11-04 21:07:18 -0600 Rating Details
2024-11-04 20:55:39 -0600 Rating Details
2024-11-04 20:44:30 -0600 Rating Details
2024-11-04 19:49:09 -0600 Rating Details
2024-11-04 19:34:28 -0600 Rating Details
2024-11-04 19:04:39 -0600 Rating Details
2024-11-04 18:39:48 -0600 Rating Details
2024-11-04 18:04:49 -0600 Rating Details
2024-11-04 15:05:05 -0600 Rating Details
2024-11-04 12:55:08 -0600 Rating Details
2024-11-05 05:38:12 -0600 Rating Details
2024-11-05 02:31:23 -0600 Rating Details
2024-11-05 02:30:03 -0600 Rating Details
2024-11-04 21:43:38 -0600 Rating Details
2024-11-04 21:08:44 -0600 Rating Details
2024-11-04 20:02:17 -0600 Rating Details
2024-11-04 18:41:21 -0600 Rating Details
2024-11-04 18:37:26 -0600 Rating Details
2024-11-04 18:35:47 -0600 Rating Details
2024-11-04 18:02:14 -0600 Rating Details
2024-11-04 17:35:39 -0600 Rating Details
2024-11-04 14:58:29 -0600 Rating Details
2024-11-05 18:57:06 -0600 Rating Details
2024-11-04 23:05:25 -0600 Rating Details
2024-11-04 22:33:37 -0600 Rating Details
2024-11-04 21:04:51 -0600 Rating Details
2024-11-04 20:23:12 -0600 Rating Details
2024-11-04 19:49:42 -0600 Rating Details
2024-11-04 19:03:12 -0600 Rating Details
2024-11-04 18:36:30 -0600 Rating Details
2024-11-04 18:13:03 -0600 Rating Details
2024-11-04 17:22:24 -0600 Rating Details
2024-11-04 15:02:50 -0600 Rating Details
2024-11-04 13:41:42 -0600 Rating Details